Cargando…

Therapeutic Effect of Bifidobacterium Administration on Experimental Autoimmune Myasthenia Gravis in Lewis Rats

Beneficial effects of probiotics on gut microbiota homeostasis and inflammatory immune responses suggested the investigation of their potential clinical efficacy in experimental models of autoimmune diseases. Indeed, administration of two bifidobacteria and lactobacilli probiotic strains prevented d...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rinaldi, Elena, Consonni, Alessandra, Cordiglieri, Chiara, Sacco, Grazia, Crasà, Camilla, Fontana, Alessandra, Morelli, Lorenzo, Elli, Marina, Mantegazza, Renato, Baggi, Fulvio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2019
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6951413/ https://www.ncbi.nlm.nih.gov/pubmed/31956324 http://dx.doi.org/10.3389/fimmu.2019.02949

Ejemplares similares

Administration of bifidobacterium and lactobacillus strains modulates experimental myasthenia gravis and experimental encephalomyelitis in Lewis rats
por: Consonni, Alessandra, et al.
Publicado: (2018)

Animal models of myasthenia gravis: utility and limitations
por: Mantegazza, Renato, et al.
Publicado: (2016)

A Novel Approach to Reinstating Tolerance in Experimental Autoimmune Myasthenia Gravis Using a Targeted Fusion Protein, mCTA1–T146
por: Consonni, Alessandra, et al.
Publicado: (2017)

Myasthenia Gravis
por: Aarli, Johan A., et al.
Publicado: (2011)

Immunoblot analysis of antiAChR antibodies in myasthenia gravis
por: Mantegazza, R., et al.
Publicado: (1988)

Complement Activation Profile in Myasthenia Gravis Patients: Perspectives for Tailoring Anti-Complement Therapy
por: Iacomino, Nicola, et al.
Publicado: (2022)

Epstein-Barr virus in tumor-infiltrating B cells of myasthenia gravis thymoma: an innocent bystander or an autoimmunity mediator?
por: Cavalcante, Paola, et al.
Publicado: (2017)

Complement Inhibition for the Treatment of Myasthenia Gravis
por: Mantegazza, Renato, et al.
Publicado: (2020)

Current and emerging therapies for the treatment of myasthenia gravis
por: Mantegazza, Renato, et al.
Publicado: (2011)

From Traditional to Targeted Immunotherapy in Myasthenia Gravis: Prospects for Research
por: Mantegazza, Renato, et al.
Publicado: (2020)

When myasthenia gravis is deemed refractory: clinical signposts and treatment strategies
por: Mantegazza, Renato, et al.
Publicado: (2018)

Impact of Ravulizumab on Patient Outcomes and Quality of Life in Generalized Myasthenia Gravis
por: Antozzi, Carlo, et al.
Publicado: (2023)

Autoimmune Thyroiditis and Myasthenia Gravis
por: Lopomo, Angela, et al.
Publicado: (2017)

Inflammation and autoimmune myasthenia gravis
por: Huda, Ruksana
Publicado: (2023)

Consistent improvement with eculizumab across muscle groups in myasthenia gravis
por: Mantegazza, Renato, et al.
Publicado: (2020)

Eculizumab improves fatigue in refractory generalized myasthenia gravis
por: Andersen, Henning, et al.
Publicado: (2019)

Editorial: Advances in Autoimmune Myasthenia Gravis
por: Punga, Anna Rostedt, et al.
Publicado: (2020)

Ravulizumab pharmacokinetics and pharmacodynamics in patients with generalized myasthenia gravis
por: Vu, Tuan, et al.
Publicado: (2023)

Correction to: Eculizumab improves fatigue in refractory generalized myasthenia gravis
por: Andersen, Henning, et al.
Publicado: (2019)

Statin‐associated necrotizing autoimmune myopathy with concurrent myasthenia gravis
por: Frasson, Emma, et al.
Publicado: (2021)

Autoimmune Myasthenia Gravis after Sternal Fracture
por: Petersen, Jens A., et al.
Publicado: (2012)

miR-146a in Myasthenia Gravis Thymus Bridges Innate Immunity With Autoimmunity and Is Linked to Therapeutic Effects of Corticosteroids
por: Bortone, Federica, et al.
Publicado: (2020)

Suppression of CHRN endocytosis by carbonic anhydrase CAR3 in the pathogenesis of myasthenia gravis
por: Du, Ailian, et al.
Publicado: (2017)

Iatrogenic Kaposi’s sarcoma in myasthenia gravis: learnings from two case reports
por: Frangiamore, Rita, et al.
Publicado: (2021)

Experimental autoimmune myasthenia: A model of myasthenia gravis in rats and guinea pigs
Publicado: (1975)

Role of complement in the pathogenesis of experimental autoimmune myasthenia gravis
Publicado: (1978)

B-Cell-Activating Factor and Autoimmune Myasthenia Gravis
por: Ragheb, Samia, et al.
Publicado: (2011)

Complicating autoimmune diseases in myasthenia gravis: a review
por: Nacu, Aliona, et al.
Publicado: (2015)

New Pathways and Therapeutic Targets in Autoimmune Myasthenia Gravis
por: Behin, Anthony, et al.
Publicado: (2018)

Pathological mechanisms in experimental autoimmune myasthenia gravis. II. Passive transfer of experimental autoimmune myasthenia gravis in rats with anti-acetylcholine recepotr antibodies
Publicado: (1976)

Summary of Research: Terminal Complement Inhibitor Ravulizumab in Generalized Myasthenia Gravis
por: Vu, Tuan, et al.
Publicado: (2023)

Development and validation of the Myasthenia Gravis TeleScore (MGTS)
por: Pasqualin, F., et al.
Publicado: (2022)

Myasthenia gravis
por: Juel, Vern C, et al.
Publicado: (2007)

Myasthenia Gravis
Publicado: (1905)

Myasthenia Gravis
por: Wilson, Andrew
Publicado: (1952)

Myasthenia Gravis
por: Bramwell, Edwin
Publicado: (1901)

VAV1 and BAFF, via NFκB pathway, are genetic risk factors for myasthenia gravis
por: Avidan, Nili, et al.
Publicado: (2014)

Whole-Genome Analysis in Korean Patients with Autoimmune Myasthenia Gravis
por: Na, Sang-Jun, et al.
Publicado: (2014)

Prophylactic Effect of Probiotics on the Development of Experimental Autoimmune Myasthenia Gravis
por: Chae, Chang-Suk, et al.
Publicado: (2012)

Prevalence and impact of autoimmune thyroid disease on myasthenia gravis course
por: Kubiszewska, Justyna, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_53559c9a2chbqselvv5dg2ohe0